Non-compliance with the re-excision guidelines for cutaneous melanoma in The Netherlands does not influence survival

被引:9
作者
Haniff, J
de Vries, E
Claassen, ATPM
Looman, CWN
van Berlo, C
Coebergh, JWW [1 ]
机构
[1] Erasmus Univ, Med Ctr, Netherlands Inst Hlth Sci, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands
[3] Twenteborg Hosp, Dept Surg, Almelo, Netherlands
[4] IKZ, Comprehens Canc Ctr S, Skin Canc Working Grp, Eindhoven, Netherlands
[5] Viecurie Hosp, Dept Surg, Venlo, Netherlands
来源
EJSO | 2006年 / 32卷 / 01期
关键词
guideline; survival; cutaneous melanoma; re-excision; compliance;
D O I
10.1016/j.ejso.2005.09.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To evaluate causes and consequences of not adhering to the clinical practice guideline for cutaneous malignant melanoma. Methods: We conducted a retrospective cohort study of the clinical records of 454 subjects whose pathological reports were obtained from a population-based cancer registry to assess determinants and effects of non-compliance of physicians with the excision policy and the related clinical practice guideline for patients with primary localized cutaneous malignant melanoma (CMM). A comparative analysis was performed of patients who did and did not undergo re-excision (compliance versus non-compliance with the guideline). Subjects diagnosed in 1988, 1993 and 1997, just 1 year after publication of the (adapted) guideline, were followed until death due to any cause or until July 1st 2003. Results: Old age was the most important determinant of non-compliance. After adjusting for age at diagnosis, gender, subsite and Breslow thickness there was no significant difference in overall survival between the compliance group and the non-compliance group. Conclusions: Non-compliance to the guideline is more common in older patients and in patients with melanoma in the head and neck region. After adjusting for confounders, a significant effect of complying with the guidelines on overall survival could not be observed. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 25 条
[1]  
BALCH CM, 1983, CANCER-AM CANCER SOC, V52, P1748, DOI 10.1002/1097-0142(19831101)52:9<1748::AID-CNCR2820520932>3.0.CO
[2]  
2-B
[3]   EFFICACY OF 2-CM SURGICAL MARGINS FOR INTERMEDIATE-THICKNESS MELANOMAS (1 TO 4 MM) - RESULTS OF A MULTIINSTITUTIONAL RANDOMIZED SURGICAL TRIAL [J].
BALCH, CM ;
URIST, MM ;
KARAKOUSIS, CP ;
SMITH, TJ ;
TEMPLE, WJ ;
DRZEWIECKI, K ;
JEWELL, WR ;
BARTOLUCCI, AA ;
MIHM, MC ;
BARNHILL, R ;
WANEBO, HJ .
ANNALS OF SURGERY, 1993, 218 (03) :262-269
[4]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[5]   Current guidelines in melanoma treatment [J].
Brochez, L ;
Verhaeghe, E ;
Sales, F ;
Del Marmol, V ;
Deraemaecker, R ;
Vossaert, K ;
Naeyaert, JM .
DERMATOLOGY, 2000, 200 (02) :160-166
[6]  
Claassen A T, 2001, Ned Tijdschr Geneeskd, V145, P2079
[7]  
COEBERGH JW, 2002, 9071229106 NED KANK
[8]  
COEBERGH JWW, 2001, CANC INCIDENCE CARE
[9]  
CohnCedermark G, 1997, CANCER-AM CANCER SOC, V80, P1418, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1418::AID-CNCR8>3.0.CO
[10]  
2-A